市場調查報告書
商品編碼
1286049
生物科技的世界市場規模,佔有率,成長分析:各技術,各用途 - 產業預測(2023年~2030年)Global Biotechnology Market Size, Share, Growth Analysis, By Technology(Nano-biotechnology, Tissue Engineering), By Application(Health, Food & Agriculture) - Industry Forecast 2023-2030 |
全球生物科技的市場規模在2021年估算為1兆2,024億4,000萬美元到2030年達到3兆8,795億1,000萬美元,在預測期間(2023年~2030年)預計將以年複合成長率13.9%的成長。製藥行業對?合成中間體的需求預計將推動市場增長,這些中間體用於生產用於強效藥物的活性藥物成分 (API)。
本報告提供全球生物科技市場相關調查分析,提供市場動態及預測,市場區隔分析,企業簡介等資訊。
Biotechnology Market size was valued at USD 1055.7 billion in 2021 and is poised to grow from USD 1202.44 billion in 2022 to USD 3879.51 billion by 2030, growing at a CAGR of 13.9% in the forecast period (2023-2030).
Utilising living objects, biological systems, or their derivatives to change or develop production processes and therapies, biotechnology is an interdisciplinary, cutting-edge discipline. It has a substantial impact on a number of industries, including food and chemical production, medicine and pharmaceuticals, genetics, and others. In tackling urgent challenges connected to environmental protection, food and energy security, and health and welfare, it plays a vital and comprehensive role. The primary drivers of the biotechnology industry are the regulatory support provided by governments of various countries, increased food demand, technical improvements to combat serious diseases, and the depletion of natural resources. However, a number of issues, such as the lengthy period it takes for research to be commercialised and societal perceptions about biotech products, are limiting the growth of the biotechnology business. Nanotechnology, cloning, and stem cell research are some of the swiftly evolving biotechnology technologies of the present.
Due to the expansion of the biotechnology industry in developing countries like China, Japan, and India, the market is being driven by advantageous government initiatives. The government authority is working to simplify the administrative process for medications, improve repayment schemes, help the item endorsement process, and streamline the clinical research process. The organisation will have a solid basis for future growth thanks to all of these measures. The lengthy lab-to-market period is one of the major market hurdles for biopharmaceutical drugs. Before a drug can be offered on the open market, it must undergo a 12- to 15-year development period. Social and ethical issues surrounding clinical trials are another hindrance to the development of the biotechnology industry.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biotechnology Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global biotechnology market is segmented based on the Technology type, end use and region. Based on Technology the Global biotechnology market is segmented into Nano-biotechnology, Tissue Engineering and Regeneration, DNA Sequencing, Cell-based Assays, Fermentation, PCR Technology, and Chromatography. Based on Application, the market is segmented into Health, Food & Agriculture, Natural Resources & Environment, Industrial Processing, Bioinformatics, and Others. Based on Region it is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.
It is thought that the prevalence of chronic diseases is rising. Chronic illnesses are more prevalent than ever. People are growing more sedentary as the middle class expands and urbanisation picks up speed. Genetic anomalies, diabetes, malaria, HIV, and other illnesses including TB and obesity are on the rise as a result. An increase in the prevalence of target diseases and genetic anomalies, ongoing technological breakthroughs in Polymerase Chain Reaction technologies, and an increase in investments, finance, and grants for scientific research are further factors influencing market revenue growth. The biopharmaceutical industry helps to ward off chronic illnesses. The biopharmaceutical industry is concentrating on developing customised treatments. As a result, individualised procedural healthcare standards will be developed and some hereditary genetic disorders will be treated.
The demand for enzymes in the pharmaceutical sector to synthesise intermediates for the creation of active pharmaceutical ingredients (API) for potent medicines is anticipated to drive market growth. The ability of an enzyme to convert complicated molecules into more basic ones (converting starch to glucose in the food and beverage industry), the elimination of fat and oil stains in the detergent industry, the production of bioethanol for use in biofuels, and improved bleaching properties in the paper and pulp industries are the factors anticipated to drive the demand for enzymes in the upcoming years.
Medical biotechnology's consequences pose a severe threat to clinical trials. The testing of the technology has led to injuries and occasionally fatalities because it is so new. These hazards should be carefully considered before using technology on humans, and anyone participating in a trial should be well-informed of the potential repercussions. People who are ill sometimes experiment with new things in the vain hope of getting better, which is a paradox. This shows that scientists and medical professionals have a serious ethical responsibility to fully inform patients of the risks and respect their final decision.
Expanding discoveries in the life sciences are offering important benefits for healthcare interventions and productivity by combining cutting-edge technologies. The development of novel techniques and their corporate acceptance have a positive effect on the biotech sector and are anticipated to significantly increase market growth. Modern technology are being used in medicine, such as 3D bioprinting. A few body parts that can be created utilising 3D bioprinting and living cells include skin, cartilage, and heart valves. The potential for developing drugs, tissues, and organs like the liver and heart using patient body cells is enormous. Accurate models for study and analysis will be made available, broadening the range of applications for human cells and tissues in medical research.
Another cutting-edge tool for monitoring a person's health that has been introduced as a result of advancements in medical technology is biosensors. Biosensors are used to keep track of a variety of biosignatures, including the heartbeat, blood pressure, body temperature, and others. With the use of this technology, medical practitioners may more easily monitor patients from a distance while also receiving crucial health data.